Title |
Intrastromal injection of bevacizumab in patients with corneal neovascularization
|
---|---|
Published in |
Arquivos Brasileiros de Oftalmologia, August 2012
|
DOI | 10.1590/s0004-27492012000400012 |
Pubmed ID | |
Authors |
Ana Carolina Cabreira Vieira, Ana Luisa Höfling-Lima, José Álvaro P. Gomes, Denise de Freitas, Michel Eid Farah, Rubens Belfort |
Abstract |
Corneal neovascularization (NV) not only reduces visual acuity, but it also causes loss of the cornea's immune privilege, strongly contributing to a worse prognosis in penetrating keratoplasty. Several mediators participate in corneal angiogenesis, and the role of vascular endothelial growth factor (VEGF) has been extensively proven. Anti-VEGF agents have been shown to be effective in slowing the growth of corneal neovessels. Bevacizumab, an anti-VEGF agent, has been successfully used in the treatment of corneal neovascularization. In this paper, we report a series of patients who underwent intracorneal bevacizumab injections to treat corneal vascularization. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 21 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 5 | 24% |
Student > Ph. D. Student | 2 | 10% |
Researcher | 2 | 10% |
Student > Master | 2 | 10% |
Student > Postgraduate | 2 | 10% |
Other | 2 | 10% |
Unknown | 6 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 33% |
Biochemistry, Genetics and Molecular Biology | 2 | 10% |
Computer Science | 2 | 10% |
Agricultural and Biological Sciences | 1 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
Other | 2 | 10% |
Unknown | 6 | 29% |